Today, the CEO of Neurocrine, Kevin Charles Gorman, exercised options of Neurocrine (NASDAQ: NBIX) for $533.4K.
Following Kevin Charles Gorman’s last NBIX Buy transaction on December 23, 2016, the stock climbed by 58.6%. Following this transaction Kevin Charles Gorman’s holding in the company was increased by 18.55% to a total of $39.78 million.
See today’s analyst top recommended stocks >>
Based on Neurocrine’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $71.09 million and GAAP net loss of $41.82 million. In comparison, last year the company earned revenue of $6.34 million and had a GAAP net loss of $59.99 million. The Company has a Price to Book ratio of 24.2259. Currently, Neurocrine has an average volume of 511.9K.
Starting in January 2017, NBIX received 101 Buy ratings in a row. 18 different firms, including Barclays and BMO Capital, currently also have a Buy rating on the stock. Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $109.00, reflecting a -9.9% downside.
The insider sentiment on Neurocrine has been positive according to 64 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.
